|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
21 July 2016 |
|
Main ID: |
NCT02827357 |
|
Date of registration:
|
06/07/2016 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation
|
|
Scientific title:
|
Review of Responses to Systemic Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation |
|
Date of first enrolment:
|
March 2013 |
|
Target sample size:
|
101 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT02827357 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Cohort, Time Perspective: Retrospective
|
|
Phase:
|
N/A
|
|
|
Contacts
|
|
Name:
|
MAZIERES Julien, MD PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
University Hospital, Toulouse |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- patients with advanced nonsmall-cell lung cancer
- known HER2 exon-20 insertion
- treated with chemotherapy and/or HER2-targeted drugs
Exclusion Criteria:
Age minimum:
18 Years
Age maximum:
N/A
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Lung Cancer
|
|
Intervention(s)
|
|
Other: No specific intervention
|
|
Primary Outcome(s)
|
|
Overall response rate
[Time Frame: 24 months]
|
|
Secondary Outcome(s)
|
|
Median progression-free survival (PFS) with conventional chemotherapy
[Time Frame: 24 months]
|
|
Secondary ID(s)
|
|
14 7305 03
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|